Interestingly, when we look at ultrasound, therapeutic ultrasound, there’s a lot of preclinical evidence in mice, in sheep, in pigs and macaques, that this is a really powerful modality. While we still have knowledge gaps, at the same time clinical trials have already started. So several groups have been using ultrasound either as a neuromodulatory modality or as a blood-brain barrier opening tool...
Interestingly, when we look at ultrasound, therapeutic ultrasound, there’s a lot of preclinical evidence in mice, in sheep, in pigs and macaques, that this is a really powerful modality. While we still have knowledge gaps, at the same time clinical trials have already started. So several groups have been using ultrasound either as a neuromodulatory modality or as a blood-brain barrier opening tool. One important study is by Ali Rezai’s group at UVA, who has been using ultrasound together with aducanumab, and they showed in a paper which came out in the New England Journal of Medicine last year, basically showing that by combining aducanumab with ultrasound, that one achieves very pronounced clearance of amyloid. So I really believe there’s utility in neurodegeneration, but for brain diseases more generally, by using it as a neuromodulatory tool, as a tool to achieve blood-brain barrier opening, but also as a tool to not only achieve blood-brain barrier opening, but to co-deliver therapeutic agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
